A dose-ranging study to determine the efficacy and safety of 1, 2, and 4 mg of dienogest daily for endometriosis

International Journal of Gynecology and Obstetrics

Volumn 108, Issue 1, 2010, Pages 21-25

  Köhler, Günter ^a   Faustmann, Thomas A ^b   Gerlinger, Christoph ^b   Seitz, Christian ^b   Mueck, Alfred O ^c  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b BAYER PHARMA AG   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Dienogest; Dose finding; Endometriosis; Pelvic pain; Progestins

Indexed keywords

DIENOGEST;

ADULT; ALOPECIA; ARTICLE; BACKACHE; BREAST DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSMENORRHEA; ENDOMETRIOSIS; FATIGUE; FEMALE; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; LAPAROSCOPY; MAJOR CLINICAL STUDY; MASTALGIA; MULTICENTER STUDY; OPTIMAL DRUG DOSE; PAINFUL DEFECATION; PATIENT COMPLIANCE; PELVIS PAIN SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SCORING SYSTEM; VAGINA BLEEDING;

EID: 71149086498     PISSN: 00207292     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijgo.2009.08.020     Document Type: Article

References (24)

1. Kennedy S., Bergqvist A., Chapron C., D'Hooghe T., Dunselman G., Greb R., et al. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod 20 10 (2005) 2698-2704
2. Hummelshoj L., Prentice A., and Groothuis P. Update on endometriosis. Women's Health 2 1 (2006) 53-56
3. Gao X., Yeh Y.C., Outley J., Simon J., Botteman M., and Spalding J. Health-related quality of life burden of women with endometriosis: a literature review. Curr Med Res Opin 22 9 (2006) 1787-1797
4. Jackson B., and Telner D.E. Managing the misplaced: approach to endometriosis. Can Fam Physician 52 11 (2006) 1420-1424
5. Prentice A., Deary A.J., Goldbeck-Wood S., Farquhar C., and Smith S.K. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev 2 (2000) CD000346
6. Vercellini P., Fedele L., Pietropaolo G., Frontino G., Somigliana E., and Crosignani P.G. Progestogens for endometriosis: forward to the past. Hum Reprod Updat 9 4 (2003) 387-396
7. Physician Information. Depo-subQ provera 104TM. Medroxyprogesterone acetate injectable suspension 104 mg/0.65 mL. Available at: http://www.drugs.com/pro/depo-subq-provera-104.html. Accessed September 8, 2009.
8. Guo S.W., Hummelshoj L., Olive D.L., Bulun S.E., D'Hooghe T.M., and Evers J.L. A call for more transparency of registered clinical trials on endometriosis. Hum Reprod 24 6 (2009) 1247-1254
9. Oettel M., Carol W., and Elger W. A 19-norprogestin without 17α-ethinyl group II: dienogest from a pharmacodynamic point of view. Drugs Today 31 (1995) 517-536
10. Köhler G., Goretzlehner G., and Amon I. Therapy of endometriosis with dienogest. [in German]. Zentralbl Gynakol 109 12 (1987) 795-801
11. Irahara M., Harada T., Momoeda M., and Tamaki Y. Hormonal and histological study on irregular genital bleeding in patients with endometriosis during treatment with dienogest, a novel progestational therapeutic agent. Reprod Med Biol 6 4 (2007) 223-228
12. Köhler G., Goretzlehner G., and Brachmann K. Lipid metabolism during treatment of endometriosis with the progestin dienogest. Acta Obstet Gynecol Scand 68 7 (1989) 633-635
13. Nikschick S., Kohler G., and Mannchen E. Carbohydrate metabolism during treatment of endometriosis with the progestin dienogest. Exp Clin Endocrinol 94 1-2 (1989) 211-214
14. Sasagawa S., Shimizu Y., Kami H., Takeuchi T., Mita S., Imada K., et al. Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. Steroids 73 2 (2008) 222-231
15. Schindler A.E., Christensen B., Henkel A., Oettel M., and Moore C. High-dose pilot study with the novel progestogen dienogest in patients with endometriosis. Gynecol Endocrinol 22 1 (2006) 9-17
16. Revised American Fertility Society classification of endometriosis: 1985. Fertil Steril 43 3 (1985) 351-352
17. Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertil Steril 67 5 (1997) 817-821
18. Moore C., Kohler G., and Muller A. The treatment of endometriosis with dienogest. Review. Drugs Today 35(Suppl C) (1999) 41-52
19. Cosson M., Querleu D., Donnez J., Madelenat P., Konincks P., Audebert A., et al. Dienogest is as effective as triptorelin in the treatment of endometriosis after laparoscopic surgery: results of a prospective, multicenter, randomized study. Fertil Steril 77 4 (2002) 684-692
20. Momoeda M., and Taketani Y. Randomized double-blind, multicentre, parallel-group dose-response study of dienogest in patients with endometriosis. Jpn Pharmacol Ther 35 7 (2007) 769-783
21. Köhler G., Lembke S., Brachmann K., Foth D., and Happke S. Behavior of parameters of liver metabolism in intermediate-term use of the gestagen dienogest in the treatment of endometriosis. [in German]. Zentralbl Gynakol 111 12 (1989) 807-810
22. Wiegratz I., Lee J.H., Kutschera E., Bauer H.H., von Hayn C., Moore C., et al. Effect of dienogest-containing oral contraceptives on lipid metabolism. Contraception 65 3 (2002) 223-229
23. Winkel C.A., and Scialli A.R. Medical and surgical therapies for pain associated with endometriosis. J Womens Health Gend Based Med 10 2 (2001) 137-162
24. Koninckx P.R., Craessaerts M., Timmerman D., Cornillie F., and Kennedy S. Anti-TNF-alpha treatment for deep endometriosis-associated pain: a randomized placebo-controlled trial. Hum Reprod 23 9 (2008) 2017-2023